Doxazosin in a gastrointestinal therapeutic system formulation

Drugs of Today

Volumn 36, Issue 10, 2000, Pages 679-688

  Cases, A ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOXAZOSIN;

ADULT; AGED; AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL ABSORPTION; HUMAN; HYPERTENSION; MALE; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0033653539     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2000.36.10.599206     Document Type: Review

References (18)

1. Doxazosin: An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia
2. A 5-year comparison of doxazosin and atenolol on blood pressure, serum lipids, and coronary heart disease risk
3. Doxazosin for benign prostatic hyperplasia: Long-term efficacy and safety in hypertensive and normotensive patients
4. Clinical correlation of maximal urinary flow and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia
5. A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy
6. The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine
7. Doxazosin in combination with atenolol in essential hypertension: A double-blind, placebo-controlled multicentre trial
8. Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension
9. The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: A randomized, placebo-controlled study
10. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT)
11. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation
12. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension
13. Use of modified-release doxazosin by physicians in clinical practice. Results from an observational study in 2000 patients
14. Vertelle der neuen Formulierung Doxazosin PP in der antihypertension Therapie: Orthostato toleranz im Vergleich zum herkommllehen Doxazosin
15. Doxazosin gastrointestinal therapeutic system versus standard doxazosin in patients with symptomatic benign prostatic hyperplasia (BPH): Results of a study in Scandinavia
16. Effects of doxazosin GITS versus standard in patients with symptomatic BPH: Results of a double-blind study
17. Blood pressure effects of doxazosin in the gastrointestinal therapeutic system formulation in hypertensive and normotensive patients with benign prostatic hyperplasia
18. α-Blockade monotherapy for hypertension and benign prostatic hyperplasia